WLWan-Hsin Lin

Wan-Hsin Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wan-Hsin Lin has a total of 131 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CIViC 2026: expanding cancer variant curation with AI, genome-wide biomarkers, and genomic regions

    by Arpad M Danos, Adam C Coffman, Susanna Kiwala, Joshua F McMichael, Kori Kuzma, Jason Saliba, Morteza Seifi, Caralyn Reisle, Cameron J Grisdale, Mariam Khanfar, et al.

    The CIViC (Clinical Interpretations of Variants in Cancer) knowledgebase (https://civicdb.org) remains one of the few free, unrestricted knowledgebases for the distribution of somatic cancer variant interpretations. CIViC leverages public curation and expert moderation to address the bottleneck problem of cancer variant interpretation for patient care. As the curation platform for ClinGen Somatic Cancer, the CIViC knowledge model is informed by multiple experts across disparate fields in cancer and, in turn, acts as a model for cancer variant classification and representation. In order to capture a wider range of genomic variations, several updates to CIViC’s data and curation model have been made with a focus on maintaining familiar workflows and user interface layouts. A new top-level entity called the Feature represents Genes, Fusions, Regions for large-scale structural variations, and Factors for genome-wide biomarkers. Accompanying Variants capture information unique to each genomic event. Molecular Profiles enable the curation of complex combinations of these Variants. CIViC has also developed a system for approval and submission of Assertions to ClinVar, guidance for the use of AI in curation and moderation of content, and additional capabilities such as source retraction monitoring and an advanced query builder.

  • Open Access

    Multi-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma

    by Diogo Moniz Garcia, Wan-Hsin Lin, Daniel P Wickland, Erik Jessen, Erik H Middlebrooks, Lauren E Haydu, Mieu Brooks, Ryan W Feathers, Lindsey Kinsella, Chris Sereduk, et al.

    Background: Glioblastoma (GBM) remains a devastating cancer with limited treatment options, largely due to its heterogeneity. While supramaximal resection has recently provided survival benefits, therapeutic profiling of different tumor compartments, particularly its infiltrative edge remains largely unexplored. Methods: Here, we leveraged magnetic resonance imaging (MRI)-guided multi-sampling, collecting 2 cores and 2 margins per case, to query GBM heterogeneity. Whole-exome and RNA-seq with drug testing in two patient-derived 3D models were used to reveal similarities and differences in genomic and transcriptomic makeups, cellular compositions, and drug responses across cores and margins. Bioinformatics interrogations further identified response biomarkers. Results: Mutation analysis showed that oncogenes exhibited a higher degree of spatial heterogeneity than tumor suppressor genes, regardless of MRI status. While the mesenchymal transcriptional subtype with extracellular matrix remodeling, stress response, and immune programs were preferentially enriched in enhancing cores, proneural tumors with neurological processes favored non-enhancing margins. Using a 15-drug GBM-targeted panel, ERK (ulixertinib) and PI3K pathway (paxalisib, CC-115) inhibitors showed preferential efficacy in enhancing cores and non-enhancing margins, respectively. The anti-apoptosis, pan-Bcl2 agent navitoclax and the epigenetic drug trotabresib represented the most effective, tumor-wide monotherapies. Importantly, drug combinations generally outperformed single agents across all regions. Conclusions: This work demonstrates the regional heterogeneity of therapeutic vulnerabilities in GBM ex vivo, showing various drugs with tumor-wide or MRI-enhancement informed activity. These findings offer preclinical bases of numerous monotherapies and drug combinations for future clinical trial design.


  • Open Access

    A Syx-RhoA-Dia1 signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in glioblastoma

    by Wan-Hsin Lin, Ryan W. Feathers, Lisa M. Cooper, Laura J. Lewis-Tuffin, Jiaxiang Chen, Jann N. Sarkaria, Panos Z. Anastasiadis

    Glioblastomas (GBM) are aggressive tumors that lack effective treatments. Here, we show that the Rho family guanine nucleotide exchange factor Syx promotes GBM cell growth both in vitro and in orthotopic xenografts derived from patients with GBM. Growth defects upon Syx depletion are attributed to prolonged mitosis, increased DNA damage, G2/M cell cycle arrest, and cell apoptosis, mediated by altered mRNA and protein expression of various cell cycle regulators. These effects are phenocopied by depletion of the Rho downstream effector Dia1 and are due, at least in part, to increased phosphorylation, cytoplasmic retention, and reduced activity of the YAP/TAZ transcriptional coactivators. Furthermore, targeting Syx signaling cooperates with radiation treatment and temozolomide (TMZ) to decrease viability in GBM cells, irrespective of their inherent response to TMZ. The data indicate that a Syx-RhoA-Dia1-YAP/TAZ signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in GBM and argue for its targeting for cancer treatment.


  • 115. Standardized assessment of Oncogenicity and clinical significance of NTRK fusions

    by Jason Saliba, Alanna J. Church, Arpad Danos, Larissa V. Furtado, Theodore Laetsch, Liying Zhang, Valentina Nardi, Wan-Hsin Lin, Deb Ritter, Marilyn M. Li, et al.

  • Open Access

    A Syx-RhoA-Dia1 signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in glioblastoma

    by Wan-Hsin Lin, Ryan W. Feathers, Lisa M. Cooper, Laura J. Lewis-Tuffin, Jann N. Sarkaria, Panos Z. Anastasiadis

    Glioblastomas (GBM) are aggressive tumors that lack effective treatments. Here, we show that the Rho family guanine nucleotide exchange factor Syx promotes GBM cell growth both in vitro and in orthotopic GBM patient-derived xenografts. Growth defects upon Syx depletion are attributed to prolonged mitosis, increased DNA damage, G2/M cell cycle arrest, and cell apoptosis, mediated by altered mRNA and protein expression of various cell cycle regulators. These effects are phenocopied by depletion of the Rho downstream effector Dia1 and are due at least in part to increased cytoplasmic retention and reduced activity of the YAP/TAZ transcriptional coactivators. Further, targeting Syx signaling cooperates with radiation treatment and temozolomide (TMZ) to decrease viability in GBM cells irrespective of their inherent response to TMZ. Taken together, the data indicate that a Syx-RhoA-Dia1-YAP/TAZ signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in GBM and argue for its targeting for cancer treatment. One Sentence Summary: Syx promotes growth and therapy resistance in glioblastoma.


  • Open Access

    Characterization and computational simulation of human Syx, a RhoGEF implicated in glioblastoma

    by Ryan J Boyd, Tien L. Olson, James D. Zook, Manuel Aceves, Derek Stein, Wan-Hsin Lin, Felicia M. Craciunescu, Debra T. Hansen, Panos Z. Anastasiadis, Abhishek Singharoy, et al.

    Structural discovery of guanine nucleotide exchange factor (GEF) protein complexes is likely to become increasingly relevant with the development of new therapeutics targeting small GTPases and development of new classes of small molecules that inhibit protein-protein interactions. Syx (also known as PLEKHG5 in humans) is a RhoA GEF implicated in the pathology of glioblastoma (GBM). Here we investigated protein expression and purification of ten different human Syx constructs and performed biophysical characterizations and computational studies that provide insights into why expression of this protein was previously intractable. We show that human Syx can be expressed and isolated and Syx is folded as observed by circular dichroism (CD) spectroscopy and actively binds to RhoA as determined by co-elution during size exclusion chromatography (SEC). This characterization may provide critical insights into the expression and purification of other recalcitrant members of the large class of oncogenic — Diffuse B-cell lymphoma (Dbl) homology GEF proteins. In addition, we performed detailed homology modeling and molecular dynamics simulations on the surface of a physiologically realistic membrane. These simulations reveal novel insights into GEF activity and allosteric modulation by the plekstrin homology (PH) domain. These newly revealed interactions between the GEF PH domain and the membrane embedded region of RhoA support previously unexplained experimental findings regarding the allosteric effects of the PH domain from numerous activity studies of Dbl homology GEF proteins. This work establishes new hypotheses for structural interactivity and allosteric signal modulation in Dbl homology RhoGEFs.

  • Open Access

    Evolution of the open-access CIViC knowledgebase is driven by the needs of the cancer variant interpretation community

    by Kilannin Krysiak, Arpad M Danos, Susanna Kiwala, Joshua F McMichael, Adam C Coffman, Erica K Barnell, Lana Sheta, Jason Saliba, Cameron J Grisdale, Lynzey Kujan, et al.

    CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org ) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. With nearly 300 contributors, CIViC contains peer-reviewed, published literature curated and expert-moderated into structured data units ( Evidence Items ) that can be accessed globally and in real time, reducing barriers to clinical variant knowledge sharing. We have extended CIViC’s functionality to support emergent variant interpretation guidelines, increase interoperability with other variant resources, and promote widespread dissemination of structured curated data. To support the full breadth of variant interpretation from basic to translational, including integration of somatic and germline variant knowledge and inference of drug response, we have enabled curation of three new evidence types (predisposing, oncogenic and functional). The growing CIViC knowledgebase distributes clinically-relevant cancer variant data currently representing >2500 variants in >400 genes from >2800 publications.